BiomX (PHGE) was upgraded to a Zacks Rank #2 (Buy) on December 28, 2025, after three consecutive upward revisions to its 2026 EPS estimates, lifting the consensus forecast by 28% over the past month. The upgrade follows management’s indication that preclinical data for its lead bacteriophage program, BX011, have demonstrated a 45% reduction in Staphylococcus aureus load in animal models. Zacks highlighted that the company’s revenue potential in chronic wound care could exceed $200 million annually upon commercialization, driving renewed analyst optimism about BiomX’s near-term financial trajectory.

On December 29, 2025, BiomX entered into definitive agreements for a private placement expected to raise $3.0 million gross proceeds through the sale of Series Y Convertible Preferred Stock and attached warrants. Each preferred share carries a stated value of $1,000, accrues dividends at 15% per annum payable quarterly, and matures in one year, convertible into common shares upon shareholder approval. The financing includes warrants exercisable for up to 3.3 million common shares over a five-year term at an initial exercise price of $2.00. Proceeds will support clinical evaluation of BX011 for diabetic foot infections and provide general corporate flexibility as the company explores strategic options.

BiomX continues to advance its proprietary BacteriOphage Lead to Treatment (BOLT) platform, which customizes phage cocktails against validated bacterial targets. With $3.0 million in fresh capital plus existing cash resources, management plans to accelerate candidate selection for additional indications, including gut dysbiosis in inflammatory bowel disease. Concurrently, the board is evaluating strategic alternatives, ranging from asset partnerships to potential M&A, with the goal of maximizing shareholder value and extending the company’s runway into 2027.